论文部分内容阅读
在这项初步的双盲对比研究中,观察用粒细胞集落刺激因子(G-CSF)治疗复发性或难治性急性髓性白血病(AML)的效果,旨在回答两个问题:(1)诱导治疗前给予G-CSF在体内是否刺激白血病细胞;(2)给予G-CSF是否可通过使静止期白血病细胞转变为化疗敏感性增殖期细胞,从而提高完全缓解(CR)率。本研究共计收入58例符合难治性AML标准的病例。病人化疗方案为米托蒽醌(MXT)7mg/m~2,静滴3天;足叶乙甙
In this initial, double-blind, controlled study, observing the efficacy of granulocyte-colony stimulating factor (G-CSF) in the treatment of recurrent or refractory acute myeloid leukemia (AML) was designed to answer two questions: (1) Does G-CSF administration stimulate leukemic cells in vivo prior to induction therapy; (2) Does G-CSF administration improve the rate of complete remission (CR) by converting quiescent leukemia cells to chemosensitive proliferative cells? This study a total of 58 cases of income consistent with refractory AML cases. Patient chemotherapy regimen was mitoxantrone (MXT) 7mg / m ~ 2, intravenous infusion for 3 days; etoposide